Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its earnings results on Wednesday, August, 2nd. The company reported ($0.50) EPS for the quarter, meeting analysts' consensus estimates of ($0.50). The firm had revenue of $23.57 million for the quarter, compared to analysts' expectations of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The company's quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.31) earnings per share. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Momenta Pharmaceuticals.

7 brokerages have issued 1 year price objectives for Momenta Pharmaceuticals' stock. Their forecasts range from $6.00 to $26.00. On average, they anticipate Momenta Pharmaceuticals' share price to reach $16.71 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Momenta’s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates. The ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Additionally, Glatopa faces competition from Teva’s thrice-weekly Copaxone. Moreover, the company's patents covering Enoxaparin Sodium Injection were declared invalid and unenforceable. Shares of the company have underperformed the industry so far in 2017. Nevertheless, sales of Glatopa 20mg continue to do well and have captured approximately 40% of the market in the U.S. In addition, a potential approval of M923 will boost investor confidence." (8/4/2017)
• 2. Cowen and Company analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
• 3. Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
• 4. Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

Some companies that are related to Momenta Pharmaceuticals include Blueprint Medicines Corporation (BPMC), Sage Therapeutics (SAGE), Ironwood Pharmaceuticals (IRWD), Intrexon Corporation (XON), Immunomedics (IMMU), Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Esperion Therapeutics (ESPR), Genus plc (GNS), Medpace Holdings (MEDP), Global Blood Therapeutics (GBT), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Albany Molecular Research (AMRI) and BeyondSpring (BYSI).

Momenta Pharmaceuticals' management team includes the folowing people:

• Craig A. Wheeler, President, Chief Executive Officer, Director
• Ganesh Venkataraman Kaundinya Ph.D., Co-Founder, Senior Vice President - Research, Chief Scientific Officer
• Scott M. Storer, Chief Financial Officer, Senior Vice President
• Bruce A. Leicher, Senior Vice President, General Counsel, Secretary
• Bruce L. Downey, Independent Director
• Corey N. Fishman, Independent Director
• Georges Gemayel Ph.D., Independent Director
• Steven C. Gilman Ph.D., Independent Director
• Jose-Carlos Gutierrez-Ramos Ph.D., Independent Director

Momenta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.16%), BlackRock Inc. (12.81%), Vanguard Group Inc. (8.51%), State Street Corp (3.48%), Palo Alto Investors LLC (2.34%) and Fiera Capital Corp (2.27%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Discovery Capital Management LLC CT, Numeric Investors LLC, Tekla Capital Management LLC, Fiera Capital Corp, Sectoral Asset Management Inc, Russell Investments Group Ltd., First Trust Advisors LP and Voya Investment Management LLC. Company insiders that have sold Momenta Pharmaceuticals stock in the last year include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach and Richard P Shea. View Insider Buying and Selling for Momenta Pharmaceuticals.

Momenta Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, Renaissance Technologies LLC, FMR LLC, Ameriprise Financial Inc., Vanguard Group Inc., TIAA CREF Investment Management LLC and State Street Corp. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $17.15.